These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28496550)

  • 21. Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.
    Leiter LA; Langslet G; Vijapurkar U; Davies MJ; Canovatchel W
    Diabetes Ther; 2016 Jun; 7(2):269-78. PubMed ID: 26984361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.
    Simes BC; MacGregor GG
    Diabetes Metab Syndr Obes; 2019; 12():2125-2136. PubMed ID: 31686884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes.
    Mikhail N
    World J Diabetes; 2014 Dec; 5(6):854-9. PubMed ID: 25512787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential Impact on Lipoprotein Subfractions in Type 2 Diabetes.
    Kamijo Y; Ishii H; Yamamoto T; Kobayashi K; Asano H; Miake S; Kanda E; Urata H; Yoshida M
    Clin Med Insights Endocrinol Diabetes; 2019; 12():1179551419866811. PubMed ID: 31452606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.
    Bashier AM; Hussain AA; Abdelgadir EI; Eltinay AT; Thadani P; Abdalla ME; Abusnana S; AlAwadi FF
    J Diabetes Metab Disord; 2015; 14():48. PubMed ID: 26064864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2017 Aug; 809():163-171. PubMed ID: 28506912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Budoff MJ; Wilding JPH
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
    Solini A; Sebastiani G; Nigi L; Santini E; Rossi C; Dotta F
    Diabetes Metab; 2017 Dec; 43(6):512-520. PubMed ID: 28499695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels.
    Bays HE; Sartipy P; Xu J; Sjöström CD; Underberg JA
    J Clin Lipidol; 2017; 11(2):450-458.e1. PubMed ID: 28502502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
    Fadini GP; Bonora BM; Avogaro A
    Diabetologia; 2017 Aug; 60(8):1385-1389. PubMed ID: 28500396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication use for the treatment of diabetes in obese individuals.
    Wilding JPH
    Diabetologia; 2018 Feb; 61(2):265-272. PubMed ID: 28501906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
    Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Gosho M; Ishii H; Shimomura I; Watada H;
    Diabetes Ther; 2017 Jun; 8(3):693-704. PubMed ID: 28516377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data.
    Yanai H; Hakoshima M; Adachi H; Kawaguchi A; Waragai Y; Harigae T; Masui Y; Kakuta K; Hamasaki H; Katsuyama H; Kaga T; Sako A
    J Clin Med Res; 2017 Jul; 9(7):605-612. PubMed ID: 28611861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.
    Lee G; Oh SW; Hwang SS; Yoon JW; Kang S; Joh HK; Kwon H; Kim J; Park D
    PLoS One; 2017; 12(5):e0177646. PubMed ID: 28542373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.
    Di Franco A; Cantini G; Tani A; Coppini R; Zecchi-Orlandini S; Raimondi L; Luconi M; Mannucci E
    Int J Cardiol; 2017 Sep; 243():86-90. PubMed ID: 28526540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.